December 16, 2021
(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) has had a busy and productive year and has grown in many ways.
On the leadership side, TIBI is proud to welcome its new Chief Scientific Officer, Xiling Shen, Ph.D. Dr Shen is a highly accomplished scientist whose works span the multidisciplinary fields of biomedical engineering, computational techniques, cancer biology, and multi-omics methodology.
December 16, 2021
(LOS ANGELES) – Billions of people around the world suffer from herpes simplex virus (HSV) infections; the severity of these infections range from no symptoms at all to fatal complications. There are two types of herpes viruses: HSV-1, which infects the eyes and oral cavity, and HSV-2, which infects the genitalia.
Current treatments include antiviral drugs which are either injected or applied topically as ointments; these drugs interfere with virus replication to keep their population in check. Other treatments are available such as vaccines, which stimulate antiviral immune responses, or immune response-modifying drugs.
December 16, 2021
(LOS ANGELES) – Established in 1992, in response to the scientific evidence supporting a rapidly changing global climate, the United Nations Framework Convention on Climate Change (UNFCCC) was adopted and became its own UN entity.
The Conference of the Parties (COP) was established as the primary annual UNFCCC conference dedicated to the intergovernmental climate change negotiations of the 197 parties (countries).
December 15, 2021
(LOS ANGELES) – From wide-ranging body movements as minute as a pulse to the various movements of joints, muscles and limbs, wearable pressure sensors placed directly on the skin may be used in myriad ways to monitor health. Other types of skin sensors can monitor health indicators through measurement of sweat and temperature on the skin’s surface.
December 3, 2021
(LOS ANGELES) – A recent announcement of their 2021 highly cited researchers was made by Clarivate Analytics. The rankings are based on research papers published from January 2010 to December 2020, with each author assigned to one of 22 fields in science and social science. Each scientist on the list is ranked in the top 1% for highly cited papers in their field.
Two scientists on the list are from the Terasaki Institute for Biomedical Innovation (TIBI); Dr. Ali Khademhosseini was named under the three categories of Biology and Biochemistry, Materials Science, and Pharmacology and Toxicology, and Dr. Mehmet R. Dokmeci was named under the Cross-Field category. Follow the links to bios and lists of their 2020 publications.
| Dr. Ali Khademhosseini, CEO and Founding Director | |
| Dr. Mehmet R. Dokmeci, Associate Professor |
November 18, 2021
(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) announces the hiring of its Chief Scientific Officer, Professor Xiling Shen. Professor Shen is a highly-accomplished scientist whose works span the multidisciplinary fields of biomedical engineering, computational techniques, cancer biology, and multi-omics methodologies.
October 25, 2021
Terasaki Institute for Biomedical Innovation’s Chief Innovation Officer Awarded Knighthood
(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation’s Chief Innovation Officer, Maurizio Vecchione, has recently been awarded the Order of Merit of the Italian Republic. The highest-ranking honor of the Republic, it is awarded for meritorious service or achievement in the fields of public service, economy, literature and the arts, as well as for social, philanthropic and humanitarian activities.
October 20,2021
Preventing Postsurgical Adhesions using Hydrogel Barriers
(LOS ANGELES)–Following surgery within the abdominal or pelvic cavities, scar tissue often forms on the inner linings of these cavities and may adhere to the organs which are found within them. This adhesion occurs in 93% of these patients and can affect the intestines, liver, urinary bladder, gall bladder and female reproductive organs. In up to 20% of adhesion cases, serious complications can arise, including chronic abdominal or pelvic pain, fertility problems or intestinal obstruction. This not only results in increased patient suffering and mortality but adds over $1 billion in additional hospital costs in the United States alone.